UB research raises consciousness for dehydration concerns in diabetic patients

December 11, 2014

BUFFALO, N.Y. -- Some drugs used to treat diabetes mimic the behavior of a hormone that a University at Buffalo psychologist has learned controls fluid intake in subjects. The finding creates new awareness for diabetics who, by the nature of their disease, are already at risk for dehydration.

Derek Daniels' paper "Endogenous Glucagon-Like Peptide-1 Reduces Drinking Behavior and Is Differentially Engaged by Water and Food Intakes in Rats," co-authored with UB psychology graduate students Naomi J. McKay and Daniela L. Galante, appears in this month's edition of the Journal of Neuroscience.

The hormone, GLP-1, works in the body to increase the release of insulin, functioning the same way as many common injectable treatments for diabetes. Extensive research has already established GLP-1's role in the control of food intake, but the new study's authors say there was a profound absence of literature on its role in fluid intake.

"Naomi picked this up early on in her graduate work and published two other papers before this one showing GLP-1 decreases fluid intake in ways that weren't appreciated before," said Daniels, whose lab studies the neurobiology of ingestive behaviors, like thirst and dehydration.

A downloadable photo of Daniels is available here: http://www.buffalo.edu/news/releases/2014/12/023.html.

When GLP-1 binds to receptors in the body it sends a signal to the brain that decreases fluid intake.

"We blocked that signaling," said McKay. "In doing so, we found an elevation in water intake."

But what sounds like straightforward behavioral pharmacology is a bit tricky when measuring incremental increases in a rat's fluid intake, especially when working with units of volume as small as the segments of time that measure computer processing speeds. Rats consume fluid in nanolitres, and since filling a teaspoon requires nearly 5 million nanolitres, researchers use a lickometer to study licking patterns.

"Licking patterns can give us hints about why rats drink more or less after an experimental manipulation," said Daniels. "In this study, we found that the rats were probably drinking more because they were feeling less full from the drinking."

Lickometers measure the number of times a rat's tongue touches an electrical port. In doing so, the rat unknowingly completes an electrical circuit at the same time the port dispenses water. Each completed circuit is one lick. The lack of any sensation protects the integrity of the count. The number of licks are tracked and then translated into a given volume of fluid.

"Clearly what we're seeing, not just in this paper, but in all three papers, is that these substances decrease drinking behavior," said Daniels. "But we're not saying people shouldn't use these drugs to treat diabetes, and we're not saying they are ineffective tools for the treatment of diabetes. However for populations already at risk for dehydration it may be something we want to be more concerned about."

These conclusions arise from what Daniels says is "a reverse-engineering approach or a reverse drug discovery approach."

"Normally, it's the basic research that informs the applied research. Basic research tells us what drugs to try for treating a disease. But in this case, we've used the drug and the clinical relevance to learn more about basic abilities of the body and how the body functions," said Daniels.
-end-
Funding for the study came from The National Institutes of Health, an American Psychological Association dissertation award and the Mark Diamond Research Fund of the Graduate Student Association at the University at Buffalo for McKay.

University at Buffalo

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.